1
Clinical Trials associated with Anti-CD19 chimeric antigen receptor T cell therapy(Wuhan Sian Medical Technology Co., Ltd)A phase II study of indigenously manufacturedHCAR19 (2nd generation Anti-CD19-4-1BB-CD3? chimeric antigen receptor T-celltherapy) in adolescent and adult patients with relapsed/refractory B-cell malignancies
Start Date19 Dec 2022 |
Sponsor / Collaborator- |
100 Clinical Results associated with Anti-CD19 chimeric antigen receptor T cell therapy(Wuhan Sian Medical Technology Co., Ltd)
100 Translational Medicine associated with Anti-CD19 chimeric antigen receptor T cell therapy(Wuhan Sian Medical Technology Co., Ltd)
100 Patents (Medical) associated with Anti-CD19 chimeric antigen receptor T cell therapy(Wuhan Sian Medical Technology Co., Ltd)
100 Deals associated with Anti-CD19 chimeric antigen receptor T cell therapy(Wuhan Sian Medical Technology Co., Ltd)